Wallace DK, Kraker RT, Freedman SF, et al. - Researchers performed a masked, multicenter, dose de-escalation study to investigate the lowest dose of intravitreous bevacizumab effective for severe retinopathy of prematurity (ROP). Participants were 59 premature infants with type 1 ROP in 1 or both eyes. In cohorts of 10 to 14 infants, 1 eye per infant received 0.016 mg, 0.008 mg, 0.004 mg, or 0.002 mg of intravitreous bevacizumab. Experts defined success as improvement by 4 days after injection and absence of recurrence of type 1 ROP or severe neovascularization needing additional treatment within 4 weeks. Based on the findings, it was concluded that 0.004 mg may be the lowest dose of bevacizumab effective for ROP.